5 completed, 1 unknown, 1 withdrawn. 3 Phase 1, 2 Not applicable, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Unknown 1 |
| Not applicable | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Myeloproliferative Syndrome, Transient: new trials by email Literature Review of Myeloproliferative Syndrome, Transient trials Research Report on Myeloproliferative Syndrome, Transient
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma the dose-escalation phase - Primary Central Nervous System Lymphoma | Phase 1 / Phase 2 | Unknown | Mingzhi Zhang | 40 | 2021-03-29 | 2022-06-02 |
| Magnetic Seizure Therapy for the Treatment of Borderline Personality Disorder MagPro MST with Cool TwinCoil, DBT - Borderline Personality Disorder | Not applicable | Completed | Centre for Addiction and Mental Health | 27 | 2017-10-17 | 2025-02-13 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease ruxolitinib phosphate, laboratory biomarker analysis, pharmacological study - Chronic Myeloproliferative Disorders, Leukemia | Phase 1 | Completed | Children's Oncology Group | 49 | 2010-09-01 | 2014-10-23 |
| Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder cytarabine, observation - Leukemia | Phase 3 | Withdrawn | Children's Oncology Group | 2006-03-01 | 2015-09-30 | |
| Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia total-body irradiation, allogeneic hematopoietic stem cell transplantation, cyclophosphamide - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder | Phase 3 | Completed | Fred Hutchinson Cancer Center | 25 | 2006-01-01 | 2014-10-31 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation - Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia | Not applicable | Completed | Fred Hutchinson Cancer Center | 160 | 2000-12-01 | 2020-01-21 |
Leukemia, Myeloid, Acute (5) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Myelomonocytic, Chronic (3) · Leukemia, Myelomonocytic, Juvenile (3) · Myeloproliferative Disorders (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Burkitt Lymphoma (2) · Congenital Abnormalities (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Intraocular Lymphoma (2) · Leukemia (2) · Leukemia, Biphenotypic, Acute (2) · Leukemia, Hairy Cell (2)
Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Leukemia, Myeloid (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Bone Marrow Diseases (4) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Neoplasms (3) · Hemorrhagic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, B-Cell (3) · Leukemia, Lymphoid (3)
Cyclosporine (2) · Mycophenolic Acid (2) · Peripheral Blood Stem Cell Transplantation (2) · Whole-Body Irradiation (2) · fludarabine phosphate (2) · Amplified Fragment Length Polymorphism Analysis (1) · Busulfan (1) · Cyclophosphamide (1) · Cytarabine (1) · Cytogenetic Analysis (1) · Dialectical Behavior Therapy (1) · Flow Cytometry (1) · In Situ Hybridization, Fluorescence (1) · MK 2206 (1) · Methotrexate (1)
Children's Oncology Group (2) · Fred Hutchinson Cancer Center (2) · Centre for Addiction and Mental Health (1) · Mingzhi Zhang (1) · National Cancer Institute (NCI) (1)
United States (4) · Canada (2) · Germany (2) · China (1) · Italy (1)
April D. Sorrell, MD (1) · Bart Scott (1) · Daniel Blumberger, MD (1) · David Maloney (1) · Jeffrey Taub, MD (1) · Maryam Fouladi (1) · Mignon Loh, MD (1)
K23HL084054 (1), P01CA018029 (1), P01CA078902 (1), P01HL036444 (1), P30CA015704 (1), U01CA097452 (1)